Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind active- and placebo-controlled study of HS-10380 in adults with acute schizophrenia
CTR20241250Phase 2Completed
- Sponsor
- 江苏豪森药业集团有限公司；上海翰森生物医药科技有限公司/ 江苏豪森药业集团有限公司
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obuprazine in schizophrenia, sponsored by 江苏豪森药业集团有限公司；上海翰森生物医药科技有限公司/ 江苏豪森药业集团有限公司. Started Apr 2024; status: completed.
02
Drugs
obuprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20241250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241250.